FibroBiologics doses first patients in Phase 1/2 trial of CYWC628 for diabetic foot ulcers

FibroBiologics, Inc.

FibroBiologics, Inc.

FBLG

0.00
  • FibroBiologics began dosing the first patients in its Phase 1/2 trial of CYWC628 for diabetic foot ulcers in early June 2026.
  • No clinical results have been presented; trial readouts are expected in the future.
  • The study is designed to assess initial safety and early signs of benefit in chronic wound healing.
  • Manufacturing scale-up advanced in parallel, with drug product from a second GMP run cleared for shipment to Australia in mid-June 2026.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fibrobiologics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606160830PRIMZONEFULLFEED9747453) on June 16, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.